Literature DB >> 19490172

Gallbladder cancer: a morphological and molecular update.

Robert David Goldin1, Juan Carlos Roa.   

Abstract

Gallbladder cancer (GBC) shows a marked geographical variation in its incidence, with the highest figures being seen in India and Chile and relatively low levels in many Western countries. Risk factors for its development include the presence of gallstones, infection and the presence of an anomalous pancreatobiliary ductal junction. It can arise from either a pathway involving metaplasia or dysplasia or one in which there is a pre-existing adenoma. The former is the more common and, because it is often not associated with a macroscopically recognizable lesion, leads to the recommendation that all gallbladders need to be examined microscopically. Accurate staging of invasive cancers is essential to determine prognosis and treatment, and this requires extensive tumour sampling. A number of genetic alterations have been identified in the preinvasive and invasive stages of GBC and they support the morphological evidence of there being two pathways by which tumours develop. Some of these genetic changes are associated with particular risk factors. For example, cases with anomalous pancreatobiliary ductal junction show a higher frequency of K-ras mutations. Some changes are associated with differences in prognosis. For example, cancers without expression of p21 but with expression for p27 have a better prognosis, whereas those that express c-erb-B2 have a worse one. Work has also been done on identifying clinical, imaging and other factors that indicate that patients have a higher risk of having GBC. This is particularly important in high-incidence areas in which GBC is a significant public health problem.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19490172     DOI: 10.1111/j.1365-2559.2008.03192.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  53 in total

Review 1.  Gallbladder cancer.

Authors:  Mislav Rakić; Leonardo Patrlj; Mario Kopljar; Robert Kliček; Marijan Kolovrat; Bozo Loncar; Zeljko Busic
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Synchronous Adenocarcinoma and Lymphoma of the Gallbladder: A Case Report.

Authors:  Rafael Parra-Medina; Patricia López Correa; Paula Castro Quiroga; Andrés Castro Arbelaez; Edgardo Yaspe Costa
Journal:  J Gastrointest Cancer       Date:  2016-12

3.  Gastrointestinal stromal tumor with synchronous gallbladder adenocarcinoma.

Authors:  Julio A Diaz-Perez; Melina Mastrodimos; Abhinay Reddy
Journal:  J Gastrointest Cancer       Date:  2014-09

4.  Organ-specific concept and controversy for premalignant lesions and carcinogenesis of gallbladder cancer.

Authors:  Keita Kai
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

5.  Expression of cell cycle-related proteins, p16, p53 and p63 as important prognostic markers in gallbladder adenocarcinoma.

Authors:  Kyungeun Kim; Dong-Hoon Kim; Seoung Wan Chae; Jun-Ho Shin; Hong Joo Kim; Sung-Im Do; Hyun Joo Lee; Ji Hae Koo; Jung-Soo Pyo; Jin Hee Sohn
Journal:  Pathol Oncol Res       Date:  2013-11-01       Impact factor: 3.201

6.  Gallbladder cancer: expert consensus statement.

Authors:  Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

7.  Different expression of S100A8 in malignant and benign gallbladder diseases.

Authors:  Wei Wang; Kai-Xing Ai; Zhou Yuan; Xin-Yu Huang; Hui-Zhen Zhang
Journal:  Dig Dis Sci       Date:  2012-07-18       Impact factor: 3.199

8.  Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.

Authors:  Nandini A Sahasrabuddhe; Mustafa A Barbhuiya; Shushruta Bhunia; Tejaswini Subbannayya; Harsha Gowda; Jayshree Advani; Braj R Shrivastav; Sanjay Navani; Pamela Leal; Juan Carlos Roa; Raghothama Chaerkady; Sanjeev Gupta; Aditi Chatterjee; Akhilesh Pandey; Pramod K Tiwari
Journal:  Biochem Biophys Res Commun       Date:  2014-03-20       Impact factor: 3.575

9.  High DBC1 (CCAR2) expression in gallbladder carcinoma is associated with favorable clinicopathological factors.

Authors:  Kyu Yeoun Won; Hyuck Cho; Gou Young Kim; Sung-Jig Lim; Go Eun Bae; Jun Uk Lim; Ji-Youn Sung; Yong-Koo Park; Youn Wha Kim; Juhie Lee
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.

Authors:  Maolan Li; Zhou Zhang; Xiaoguang Li; Junyi Ye; Xiangsong Wu; Zhujun Tan; Chang Liu; Baiyong Shen; Xu-An Wang; Wenguang Wu; Daizhan Zhou; Di Zhang; Ting Wang; Bingya Liu; Kai Qu; Qichen Ding; Hao Weng; Qian Ding; Jiasheng Mu; Yijun Shu; Runfa Bao; Yang Cao; Peizhan Chen; Tianyu Liu; Lin Jiang; Yunping Hu; Ping Dong; Jun Gu; Wei Lu; Weibin Shi; Jianhua Lu; Wei Gong; Zhaohui Tang; Yong Zhang; Xuefeng Wang; Y Eugene Chin; Xiaoling Weng; Hong Zhang; Wei Tang; Yonglan Zheng; Lin He; Hui Wang; Yun Liu; Yingbin Liu
Journal:  Nat Genet       Date:  2014-07-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.